Endo

PDF

Biocompatibility of the different portions of the content of AH Plus® sealer tubes through subcutaneous implantation

Josete Veras Viana portela, Rielson José Alves Cardoso, Cássio José Alves de Sousa, Huang Huai Ying

Objective: Following the ISO/FDI and ANSI/ADA criteria, this study evaluated tissue response to the resinous sealer AH Plus®, analyzing its initial, middle and final tube segments as well as the total mixture of the two pastes that comprises it. This methodology was based on the clinical observation of the differences in consistency, homogeneity and fluidity of this sealer according to which part of the tube is used. Methods: Two subcutaneous implants were carried out in the dorsal region of 5 guinea pigs (Cavia porcellus) for each portion of the tested sealer and total mixture. The observation periods were 30 and 90 days. The animals were sacrificed and the implants were removed and histologically processed to obtain serial sections which were stained using hematoxylin and eosin. Results: The histological evaluation using an optical microscope at 20x, 100x, 200x, 400x and 1000x magnifications showed that the sealer induced moderate to severe inflammatory response at 30 days with expressive inflammatory infiltrate, which decreased to moderate to mild response at 90 days, with mild or moderate inflammatory infiltrate. There was no significant difference between the segments of the tube. Conclusion: This evaluation led to the conclusion that the studied sealer does not present conditions of biocompatibility within the parameters and the experimental conditions adopted and there is no biological difference between the initial, medium and final segments or complete mixture of the two pastes.

Keywords: Biocompatible materials. Subcutaneous tissue. Endodontics.

How to cite: Portela JVV, Cardoso RJA, Sousa CJA, Ying HH. Biocompatibility of the different portions of the content of AH Plus® sealer tubes through subcutaneous implantation. Dental Press Endod. 2011 Oct-Dec;1(3):56-64.

Thursday, April 18, 2024 23:50